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The role of bradykinin in the antifibrotic actions of perindoprilat
on human mesangial cells.
Background. Angiotensin-converting enzyme inhibitors
(ACE-I) protect against the development of glomeruloscle-
rosis using mechanisms partly dissociated from their systemic
antihypertensive action. The aim of the current study was to
delineate the mechanism of action underlying the antifibrotic ef-
fects of the ACE-I perindoprilat in the context of macrophage-
mediated scarring in human mesangial cells.
Methods. Mesangial cells were treated with macrophage-
conditioned medium (MPCM) in the presence or absence of
the ACE-I perindoprilat.
Results. Forty lmol/L perindoprilat reduced MPCM-induced
mesangial cell fibronectin levels by 19.4 ± 0.6% (P < 0.001). Im-
munoprecipitation of 35S-methionine biosynthetically labeled
fibronectin and Northern analysis suggested that the decrease in
fibronectin levels was not caused by reduced synthesis. MPCM
stimulated the production of matrix metalloproteinases (MMP)
2, 3, and 9 in mesangial cells; however, these were not signifi-
cantly altered by ACE-I treatment, and neither was production
of their tissue inhibitor of metalloproteinases (TIMP-1). Ad-
dition of exogenous bradykinin to MPCM-treated mesangial
cells resulted in a 22.5 ± 1.4% (P < 0.02) reduction in secreted
fibronectin levels, while semiquantitative reverse transcription-
polymerase chain reaction (RT-PCR) and Southern blotting
demonstrated that bradykinin B2 receptor expression was up
regulated by 71 ± 30% in MPCM-stimulated mesangial cells
in response to ACE-I treatment (P = 0.032). Moreover, the
bradykinin B2 receptor antagonist HOE 140 attenuated the
beneficial effects of perindoprilat. MPCM-stimulated mesan-
gial cell protein expression levels of plasminogen activator
system components tissue plasminogen activator (tPA) and
plasminogen activator inhibitor-1 (PAI-1) were altered after
treatment with ACE-I.
Conclusion. These results suggest that ACE-I-induced reno-
protection, in the context of macrophage-stimulated mesangial
cell scarring, is mediated, at least in part, via the actions of
bradykinin.
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activator (uPA), plasminogen activator inhibitor-1 (PAI-1).
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Angiotensin-converting enzyme inhibitors (ACE-I)
have proved to be effective in reducing proteinuria and
deposition of extracellular matrix within the kidney,
thereby attenuating the progression of renal failure in
patients with a variety of renal diseases [1–6]. These
renoprotective effects are greater than those seen with
other antihypertensive agents, including calcium chan-
nel blockers [7]. This has led to the speculation that the
renoprotective actions of ACE inhibitors are additional
to any beneficial effects arising from their systemic an-
tihypertensive actions [6, 8, 9]. Experimentally, ACE in-
hibitors have been shown to lower the intraglomerular
capillary hypertension, which is thought by many to be
etiologically important in the development of glomeru-
losclerosis and chronic renal failure. Such effects on in-
traglomerular hemodynamics may explain the additional
renoprotective effects seen with this class of antihyper-
tensive agents. However, nonhemodynamic renoprotec-
tive actions are also possible. These may be explained
by the intrarenal actions of the renin-angiotensin sys-
tem (RAS). In vivo transfection of genes for renin and
angiotensinogen into glomerular cells has been shown
to induce extracellular matrix expansion in glomeruli,
with concomitant expression of mesangial cell smooth
muscle actin [10]. Angiotensin II, the product of ACE
activity, has been shown to stimulate matrix protein syn-
thesis via the transforming growth factor b (TGFb) axis
[11], and to promote mesangial cell hypertrophy and hy-
perplasia [11]. Modulation of the local RAS, and partic-
ularly, reducing Ang II generation via ACE inhibition,
might therefore be expected to reduce the tendency for
glomerular extracellular matrix production, and hence,
the development of glomerulosclerosis.
Because ACE also catalyzes the degradation of
bradykinin [12], it is thought that ACE-I may, in addi-
tion, exert their beneficial actions by protecting endoge-
nously produced kinins from degradation. The resulting
enhanced local levels of peptide may then contribute to
the observed beneficial effects [13].
While in vivo studies can focus on the final outcome
of the beneficial effects of ACE inhibitor treatment, the
mechanisms underlying the protective effects are difficult
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to define because contributions from the modulation of
renal hemodynamics can never be discounted. We have
previously demonstrated that macrophages and their se-
creted products are able to up-regulate mesangial cell
matrix production in vitro. Such observations provide po-
tential mechanisms whereby an influx of macrophages
into the glomerulus in vivo may promote glomeruloscle-
rosis [14].
The aim of the current study was to delineate the mech-
anism of action underlying the renoprotective, or more
specifically, antifibrotic effects of ACE inhibitors in the
context of a macrophage-mediated mesangial cell scar-
ring process using an in vitro approach.
METHODS
Unless otherwise stated, all reagents were purchased
from Sigma-Aldrich Chemical Co. (Dorset, UK).
Cell culture
Human mesangial cells were cultured, using standard
serial sieving techniques, from the glomerular explants of
human kidney specimens derived from the normal poles
of nephrectomized kidneys from patients with renal carci-
noma. The cells were cultured in RPMI 1640 (Invitrogen,
Paisley, UK), supplemented with 20% heat-inactivated
fetal calf serum (FCS), 100 U/mL penicillin (Invitrogen),
100 lg/mL streptomycin (Invitrogen), 5 lg/mL bovine
insulin, and 2 mmol/L glutamine (Invitrogen). Cul-
tured cells were characterized by their stellate fusiform
morphology, their positive staining for actin, myosin,
vimentin, and desmin, and negative staining for factor
VIII-related antigen and cytokeratin.
Mesangial cells of passages 2 through 8 were cultured in
24-well plates (Costar-Corning, Buckinghamshire, UK)
or 25 cm2 flasks (Costar-Corning), allowed to grow to con-
fluence, and then rendered quiescent in RPMI medium
containing 0.5% FCS for 48 hours before use.
Cells of the human monocyte/macrophage cell line
U937 (ECCAC no. 85011440) were grown in RPMI
1640 supplemented with 10% FCS, 100 U/mL penicillin,
100 lg/mL streptomycin, and 2 mmol/L glutamine.
Preparation of U937 cell-conditioned medium
U937 cells were seeded into 75 cm2 at a cell density
of 106 cells per mL in serum-free RPMI 1640 (100 U/mL
penicillin, 100 lg/mL streptomycin, 2 mmol/L glutamine)
and stimulated with 10−8 mol/L phorbol 12-myristate 13-
acetate (PMA) to allow them to adhere to the plastic
substratum. Adherent cells were then stimulated with
lipopolysaccharide (LPS) (from Escherichia coli 026 B6)
at a final concentration of 1 lg/mL in serum-free RPMI
1640 for 16 hours. After washing 3 times with Hank’s bal-
anced salt solution (HBSS; Invitrogen), the cells were cul-
tured for another 30 hours in serum-free RPMI 1640. The
conditioned medium (MPCM) was harvested and cen-
trifuged for 5 minutes at 1000 rpm and frozen at −20◦C
until required.
Culture of mesangial cells in the presence of MPCM
Confluent, quiescent mesangial cells were exposed to a
50% solution of MPCM in the presence or absence of the
ACE inhibitor perindoprilat (a gift from Servier, France).
The cultures were maintained in this medium for 1 or 3
days. The tissue culture supernatants were harvested and
stored at −20◦C for subsequent analysis.
Mesangial cells were additionally treated with MPCM
± 0.1 lmol/L bradykinin or MPCM ± ACE-I ± 1 lmol/L
bradykinin B2 receptor antagonist HOE 140.
For Northern and Southern analyses, mesangial cells
were exposed to 50% MPCM ± additions for 18 hours
before RNA processing.
Preparation of cell lysates
After removal of tissue culture supernatants, cell
monolayers were washed with phosphate-buffered saline
solution (PBS), scraped into 250 lL 1% Nonidet P40 in
wash buffer (PBS containing 0.3 mol/L NaCl and 1%
Tween 20), and then incubated at room temperature (RT)
for approximately 30 minutes. The cell scrapings were
transferred to 2 mL tubes, sonicated with a 5-second
burst, and centrifuged for 1 minute at 11,600g. Sonication
and centrifugation were repeated, and the lysate super-
natants were assayed for fibronectin and total cell protein.
ELISAs
Culture supernatants and cell lysates were assayed
for fibronectin using a modified version of an “in
house” enzyme-linked immunosorbent assay (ELISA)
[15]. Briefly, 96-well microtiter plates (Costar-Corning)
were coated with 100 lL/well rabbit antihuman fi-
bronectin antibody (in 0.05 mol/L carbonate buffer, pH
9.6) at 4◦C overnight. The plates were blocked with 2%
bovine serum albumin (BSA) (in wash buffer) for 1 hour
at RT. After washing the plates 4 times, 50 lL/well of
human fibronectin standard (2000–31.3 ng/mL in dou-
bling dilutions), supernatant, or cell lysate were added
to the wells and incubated for at least 2 hours at RT.
After another 4 washes, 50 lL of monoclonal antihu-
man fibronectin antibody was added and incubated for
1 hour at RT. After washing, 50 lL of rabbit antimouse
immunoglobulin G (IgG) conjugated to horseradish per-
oxidase (HRP) (Dako, Ltd., Ely, UK) was added to the
wells and incubated at RT for 1 hour. After 4 more washes,
50 lL of 0.67 mg/mL 1,2 phenylenediamine dihydrochlo-
ride was added in 0.03 mol/L citrate buffer, pH 5.0,
containing 0.012% H2O2. Following color development,
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75 lL of 1 mol/L H2SO4 were added to stop the reac-
tion, and absorbance was read at 492 nm on a Titertek
MultiskanPlus microtiter plate reader (Flow Laborato-
ries, Oxfordshire, UK).
The following ELISAs were carried out according
to manufacturer’s instructions: (1) bradykinin enzyme
immunoassay (EIA) (Peninsula Laboratories, Inc., St.
Helens, Merseyside, UK); (2) BIOTRAK matrix met-
alloproteinase (MMP)3, MMP2, and tissue inhibitor of
metalloproteinase-1 (TIMP-1) (Amersham Pharmacia
Biotech, Hertfordshire, UK); (3) Quantikine MMP 9
(R&D Systems, Abingdon, Oxon, UK); (4) Quantima-
trix human laminin (Chemicon International, Temecula,
CA, USA); (5) Immunolyse tissue plasminogen activator
(tPA) and Immunolyse plasminogen activator inhibitor-1
(PAI-1) (Biopool International, CA, USA); (6) urokinase
plasminogen activator (uPA) (Oncogene Science, Bayer
Diagnostics, East Walpole, MA, USA).
Zymography
MMP2 and MMP9 activities were determined using
gelatin zymography. Cell supernatants were diluted 1:5 in
PBS, 30 lL of the dilution was mixed with an equal vol-
ume of nonreducing sample buffer and loaded on a 10%
sodium dodecyl sulfate (SDS) polyacrylamide gel con-
taining 1 mg/mL gelatin. After electrophoresis at 4◦C, the
gels were washed in 2 changes of 2.5% (v/v) Triton X-10
at RT, after which they were incubated overnight at 37◦C
in activation buffer (50 mmol/L Tris-HCl, 100 mmol/L
NaCl, 10 mmol/L CaCl2, 0.05% Brij 721). The gels were
then stained for at least 2 hours with Brilliant Blue R,
and destained in an aqueous solution methanol:acetic
acid:water (40:10).
Protein determination
The protein content of cell lysates dissolved in 1%
Nonidet NP40 was determined using a commercial Bio-
Rad detergent compatible (DC) protein assay, using BSA
standards according to the manufacturer’s instructions.
Northern blotting
Northern analysis was carried out using a method
previously described [14]. Briefly, total RNA was ex-
tracted from mesangial cells using TRIzol reagent (Invit-
rogen). Thirty-lg aliquots of RNA were resolved on a 1%
agarose-formaldehyde gel [in 3-[N-morpholino]propane
sulfonic acid (MOPS)], blotted onto a Hybond-N ny-
lon membrane (Amersham Pharmacia), and hybridized
with a [32P]-dCTP cDNA probe that had been labeled
using a random primer labeling system (Prime-a-Gene;
Promega, Southampton, UK) in a solution containing
50% formamide, 1% SDS, 5× Denhardt’s, 5× SSPE, and
200 lg/mL denatured salmon sperm DNA at 42◦C. Mem-
branes were exposed to X-Omat AR (Kodak, Hemel,
Hempstead, UK) or Biomax MS (Kodak, UK) films with
X-Omatic or Biomax transcreen HE intensifying screens
(Kodak, UK), respectively, at −70◦C. The resulting au-
toradiographs were scanned using a BioRad GS 700 imag-
ing densitometer. RNA loading was normalized using a
cDNA probe for the nonstructural protein cyclophilin.
Cyclophilin expression was not affected by treatment
with MPCM.
RT-PCR
Aliquots of total RNA (0.5 lg) were reverse-
transcribed using avian myeloblastosis virus (AMV) re-
verse transcription system (Promega) according to the
manufacturer’s instructions. The resulting cDNA was am-
plified using ReddyMixTM PCR Mastermix (ABgene,
Surrey, UK) and 50 pmol of specific sense and antisense
primers.
Thermocycling conditions were: 1 cycle at 94◦C for
5 minutes, 35 cycles of 94◦C for 30 seconds, 55◦C for
1 minute, 68◦C for 2 minutes, 1 cycle at 68◦C for 7 minutes,
and 10-minute soak at 4◦C.
Southern blotting
Aliquots of reverse transcription-polymerase chain
reaction (RT-PCR) cDNA (20 lL) were resolved on
1% Tris-acetate EDTA (TAE)-agarose gels. The gels
were denatured for 45 minutes in a solution containing
1.5 mol/L NaCl and 0.5 mol/L NaOH. The gels were
rinsed in water, and then neutralized in a solution con-
taining 1.5 mol/L NaCl and 0.5 mol/L Tris-HCl, pH 7.5.
Thereafter, the gels were blotted and hybridized as de-
scribed for Northern blotting.
Oligonucleotide primers
Probes were created by RT-PCR of RNA extracted
from mesangial cells stimulated with MPCM followed by
amplification using the following primers:
Bradykinin B2 sense 5′-ATG CTC AAT GTC ACC
TTG CAA-3′, antisense 5′-CTG ATG ACA CAA GCG
GTG ACG-3′. tPA sense 5′-GAC TGG ACG GAG TGT
GAG CTC TCC-3′, antisense 5′-GTC TAC ACC AAG
GTT ACC AAC TAC-3′ [16]. PAI-1 sense 5′-GTG CAC
CAT CCC CCA TCC TAC GTG-3′, antisense 5′-GGG
TTC CAT CAC TTG GCC CAT GAA-3′ [17]. Kininogen
sense 5′-CTA GAT TGC AAC GCT GAA G-3′[18]. High
kininogen antisense 5′-GTC ATG TCT ACG AGT ATG
C-3′ [18]. Low kininogen sense 5′-GTC ACC TAA GGT
CCT GCG AG-3′ antisense 5AGG CAG AGT GAT
AAA ATG GC-3′[19]. Tissue kallikrein sense 5′-AAC
ACA GCC CAG TTT GT-3′, antisense 5′-CTT CAC ATA
AGA CAG CAC-3′ [20].
The PCR products were validated by sequencing using
the ABI PRISMTM dRhodamine Terminator Cycle Se-
quencing Ready Reaction Kit (PE Applied Biosystems,
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Perkin-Elmer Corporation, Warrington, UK) according
to manufacturer’s instructions.
Metabolic labeling/immunoprecipitation
Confluent, quiescent mesangial cells were stimulated
with MPCM in the presence or absence of perindoprilat
or medium alone diluted 1:1 in methionine-free RPMI.
Each well was pulsed with 20 lCi 35S-methionine (ICN
Flow). After 3 days, the culture supernatants were re-
tained, and the cell monolayers were washed twice in
PBS. Cell lysates were prepared as described above.
To immunoprecipitate the newly synthesized fibronectin,
20 lL of rabbit antihuman fibronectin antibody was
added to 400 lL culture medium for approximately
4 hours. Antigen:antibody complexes were precipitated
with 50 lL of insoluble protein A cell suspension (10%
wet vol/vol of nonviable Staphyloccocal aureus cells
(Cowan strain) by overnight incubation at 4◦C. The sam-
ples were centrifuged for 10 minutes at 3000g, and the
pellets were washed 3 times with ice-cold immunopre-
cipitation buffer (PBS containing 0.5 mol/L NaCl, 0.1%
SDS, and 1% Triton X-100, pH 7.4), vortexing the pel-
let thoroughly between each wash. The pellets were dis-
solved in 70 lL sample buffer and boiled for 7 minutes.
The dissolved pellets were resolved by electrophoresis
on 5% SDS-polyacrylamide gels. Newly synthesized fi-
bronectin was detected by autoradiography of dried gels.
Bands were quantified by scanning densitometry on a
BioRad densitometer.
Bradykinin receptor radioligand-binding assays
Mesangial cells in 24-well culture plates were exposed
to MPCM, MPCM ± perindoprilat, or medium alone for
18 hours. The cells were then placed on ice, and 500 lL
aliquots of the culture supernatant were removed and re-
tained. Prolyl2,4−3,4(n)-3H-bradykinin [2 lL (0.04 lCi)]
(Amersham Biosciences) was then added to the remain-
ing 500 lL of culture medium in each well and incu-
bated on ice in a refrigerator at 4◦C for 2 hours. To
determine nonspecific binding (NS), 10 lmol/L unlabeled
bradykinin was added to some of the wells that had been
treated with 3H-bradykinin. After the 4◦C incubation, the
culture supernatants were removed, and the cells were
washed with cold Tris-buffered saline (TBS), pH 8.0. The
cell monolayers in each well were scraped into 210 lL
of 0.5 mol/L NaOH. The plates were then incubated at
65◦C for 15 minutes to solubilize the protein. A portion
of each cell lysate (180 lL) or 200 lL of retained radioac-
tive culture supernatant was placed into scintillation vials
containing 4 mL Ecoscint scintillation fluid (National Di-
agnostics, Hull, UK) and 50 lL concentrated HCl. Counts
per minute (cpm) were determined on a liquid scintil-
lation counter (LKB Wallac; Beckman Coulter, Fuller-
ton, CA, USA). Bradykinin binding in cell lysates (cpm)
as a percentage of total bradykinin input and correcting
for nonspecific binding is expressed as a function of cell
protein.
STATISTICS
Mesangial cell fibronectin levels were corrected for
cell protein. Fibronectin levels have been expressed as
fold-increase over control (medium) levels. Where ap-
propriate, data in other experiments were expressed as
percent of MPCM-stimulated levels. Representative au-
toradiographs of Northern or Southern blots are shown,
but densitometric analysis incorporates data from all ex-
periments after normalization for the appropriate house-
keeping gene. Results are expressed as mean ± SEM. For
comparison of the mean between two groups, an unpaired
t test was employed. Statistical significance was defined
as P < 0.05.
RESULTS
Effect of perindoprilat on mesangial cell
fibronectin levels
Stimulation of confluent, quiescent mesangial cells
with MPCM for 3 days resulted in a 79 ± 15% increase
in secreted, and a 77 ± 17% increase in cell-associated,
fibronectin levels (P < 0.001) over those of control cells
(medium alone) (Fig. 1). Addition of 40 lmol/L perino-
prilat significantly attenuated this response, resulting
in decreases in MPCM-stimulated fibronectin levels of
19.4 ± 0.6% (P < 0.001) and 21.7 ± 1.0% (P < 0.001)
for secreted and cell-associated fibronectin levels, respec-
tively (Fig. 1). The dose of 40 lmol/L had previously been
determined as optimal from a dose-response curve car-
ried out in preliminary experiments (data not shown).
Addition of 1 lmol/L LPS to mesangial cells had no ef-
fect on fibronectin production (data not shown).
Similarly, perindoprilat reduced MPCM-stimulated su-
pernatant laminin protein levels by 23.2 ± 1.72% (P =
0.001) (data not shown).
Effect of perindoprilat on fibronectin synthesis
In order to assess whether the fibronectin levels had
decreased because of a reduction in synthesis, immuno-
precipitation of metabolically labeled 35S-methionine-
fibronectin in the presence or absence of 40-lmol/L
perindoprilat was carried out. The resulting autoradio-
graphs demonstrated that perindoprilat did not appear
to decrease fibronectin protein synthesis (Fig. 2). More-
over, this was supported by Northern blot analysis, in
which fibronectin mRNA levels were unchanged in the
presence of perindoprilat (Fig. 3).
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Fig. 1. Effect of perindoprilat on mesan-
gial cell fibronectin levels. Confluent, qui-
escent cultures of human mesangial cells
were treated with MPCM ± 40 lmol/L
perindoprilat for 3 days. Culture super-
natants and cell lysates were assayed for fi-
bronectin. Results are expressed as mean ±
SEM (fold-increase over medium alone and
corrected for cell protein). ∗P < 0.001 vs.
medium alone; ∗∗P < 0.001 vs. MPCM,
N = 14. MPCM, macrophage-conditioned
medium; Med, medium; ACE-I, angiotensin-
converting enzyme inhibitor.
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Fig. 2. Effect of perindoprilat on fibronectin synthesis. Representative
autoradiograph of immunoprecipitated 35S-methionine-fibronectin ob-
tained from the culture supernatants of mesangial cells incubated in
the presence of MPCM ± 40 lmol/L perinoprilat. A representative
blot from 3 experiments is shown. MPCM, macrophage-conditioned
medium; Med, medium; ACE-I, angiotensin-converting enzyme
inhibitor.
Effect of perindoprilat on fibronectin degradation
Because a decrease in fibronectin levels can also oc-
cur as a result of matrix degradation we investigated pa-
rameters which may be involved in matrix degradation.
Tissue culture supernatant levels of the MMP 2, 3, and
9 were measured by ELISA. While MPCM up-regulated
MMP levels over control (medium alone), total MMP
protein levels were not significantly changed by treatment
with perindoprilat, and neither was expression of TIMP-1
(Table 1). Gelatin zymography confirmed these data,
demonstrating that there was no difference in MMP2 or 9
activities following ACE treatment of MPCM-stimulated
mesangial cells (data not shown). Together these data
suggest that if ACE-I induced degradation was occurring,
it was being mediated by proteinases other than MMP 2,
3, and 9.
MPCM MedMPCM
+
ACE-I
Fibronectin
Cyclophilin
Fig. 3. Effect of perindoprilat on fibronectin mRNA levels. Northern
analysis probing for fibronectin was carried out on RNA extracted from
mesangial cells incubated with MPCM ± 40-lmol/L perindoprilat for
18 hours. A representative blot from 4 experiments is shown. MPCM,
macrophage-conditioned medium; Med, medium; ACE-I, angiotensin
converting enzyme inhibitor.
Table 1. Effect of perindoprilat on supernatant levels of matrix
metalloproteinases (MMPs 2, 3, 9) and tissue inhibitor of
metalloproteinases (TIMP-1)
P value vs.
ng/mL MPCM MPCM + ACE-I Medium MPCM
MMP-2 3.7 ± 0.65 2.7 ± 0.5 1.7 ± 0.4 0.228
MMP-3 8.1 ± 3.1 7.4 ± 3.2 0 0.873
MMP-9 5.5 ± 0.3 5.8 ± 0.5 0.5 ± 0.4 0.12
TIMP-1 346 ± 75 390 ± 69 220 ± 66 0.683
Renin-angiotensin and kallikrein-kinin systems
ACE activity could not be detected in our super-
natants or MPCM at the sensitivity levels of an automated
Sigma ACE detection assay. However, ACE gene expres-
sion was detected by semiquantitative RT-PCR, and was
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Fig. 4. Expression of renin angiotensin
and kallikrein-kinin systems in human
mesangial cells. (A) RNA from control
mesangial cells was reverse transcribed and
amplified by polymerase chain reaction
(PCR) using the appropriate primers. PCR
products were resolved by electrophoresis
on Tris-acetate EDTA (TAE) agarose gels.
Gels reveal the presence of the components
of kallikrein-kinin and renin-angiotensin
systems in human mesangial cells. (B) RNA
from mesangial cells treated with MPCM ±
perinoprilat or medium alone was reverse
transcribed and the gene for low kininogen
amplified by PCR and Southern blotted. A
representative autoradiograph is presented.
Densitometry includes data from 4 indepen-
dent experiments. Abbreviations are: LK,
low kininogen; HK, high kininogen; KALL,
kallikrein; A’GEN, angiotensinogen; MPCM,
macrophage-conditioned medium; Med,
medium; ACE-I, angiotensin-converting
enzyme inhibitor; TAE, Tris-acetate EDTA.
found not to change in response to ACE-I treatment (data
not shown). ACE provides a common link between the
renin-angiotensin and the kallikrein-kinin systems—two
interactive, but often antagonistic, systems involved in
renal homeostasis. Inhibition of ACE activity results not
only in a decrease in Ang II levels, but is accompanied by
an increase in local levels of bradykinin. Semiquantita-
tive RT-PCR demonstrated that mesangial cells not only
expressed all the components of the RAS (renin, ACE
and angiotensinogen) but they also expressed message
for high and low kininogens and the serine protease tis-
sue kallikrein (Fig. 4A), confirming that mesangial cells
possess the biochemical machinery necessary to generate
vasoactive kinins from an endogenous source.
In addition, semiquantitative RT-PCR demonstrated
that MPCM stimulation reduced mesangial cell expres-
sion levels of low kininogen, the preferred bradykinin
precursor in the kidney, below basal levels. Treatment
with perindoprilat partially attenuated this reduction, re-
turning levels closer to those of the control (Fig. 4B).
The role of bradykinin
We investigated the possibility that raised bradykinin
levels may play a role in the observed antifibrotic effects.
Bradykinin (0.1 lmol/L) was added directly to MPCM-
stimulated and control mesangial cells. This resulted in
a 21.5 ± 1.4% (P < 0.02 vs. MPCM) reduction in se-
creted fibronectin levels compared with those induced
by MPCM alone (Fig. 5). Bradykinin also significantly
decreased basal fibronectin levels by 14.1 ± 0.4% (P <
0.001) (Fig. 5).
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Fig. 5. Effect of exogenous bradykinin on MPCM-stimulated mesan-
gial cell fibronectin levels. Mesangial cells were stimulated with MPCM
± 0.1 lmol/L bradykinin for 3 days. Supernatants were assayed for fi-
bronectin by enzyme-linked immunosorbent assay (ELISA). Results
are expressed as mean ± SEM (Fibronectin levels are expressed as a
fold-increase over medium alone and corrected for cell protein). ∗∗P <
0.02 vs. MPCM alone; ∗P > 0.001 vs. medium alone, N = 5. Abbrevi-
ations are: MPCM, macrophage-conditioned medium; Med, medium;
Bk, bradykinin.
Paradoxically, however, mesangial cell culture super-
natant levels of bradykinin at day 3, as measured by EIA,
were found to be significantly reduced following treat-
ment with perindoprilat, and not increased as might have
been expected (2.75 ± 0.64, ∗1.46 ± 0.23, 0.56 ± 0.08 pg
bradykinin/lg cell protein for MPCM, MPCM + perindo-
prilat, medium alone, respectively, ∗P = 0.036 vs. MPCM)
(Fig. 6).
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Fig. 6. Effect of perindoprilat on supernatant bradykinin levels.
Mesangial cell culture supernatants from cells stimulated with MPCM
± 40 lmol/L perindoprilat were assayed for bradykinin by enzyme
immunoassay (EIA). Results are expressed as mean ± SEM (pg
bradykinin/lg cell protein). ∗P = 0.002 vs. MPCM alone, N = 6. Abbre-
viations are: MPCM, macrophage-conditioned medium; Med, medium;
ACE-I, angiotensin-converting enzyme inhibitor.
Effect of perindoprilat on bradykinin receptor expression
One possible explanation for the observed decrease
in bradykinin levels could be that ACE-I treatment up-
regulates the expression of the bradykinin B2 receptor,
with the result that more bradykinin is sequestered from
the local surroundings via ligation to receptors on the cell
membrane.
Semiquantitative RT-PCR and Southern blotting of
RNA from mesangial cells stimulated with MPCM
demonstrated that bradykinin B2 receptor expression
was indeed significantly up-regulated 71 ± 30% (P =
0.032) in the presence of perindoprilat (Fig. 7).
Moreover, bradykinin B2 receptor binding using 3H-
bradykinin supported these observations at protein level.
More 3H-bradykinin (71.0 ± 15.0%) bound to the surface
of ACE-I–treated mesangial cells than nontreated cells
(∗P = 0.002 vs. MPCM alone) (Fig. 8).
Effect of bradykinin-B2 receptor inhibitor HOE 140
If the antifibrotic effects of perindoprilat were me-
diated by ligation of bradykinin to the B2 receptor,
treatment with a selective bradykinin B2 receptor antag-
onist would be expected to attenuate the beneficial ef-
fects of the ACE-I. Incubation of mesangial cells with the
bradykinin B2 receptor antagonist HOE 140 (1 lmol/L)
MPCM MedMPCM
+
ACE-I
GAPDH
Bk-B2
Fig. 7. Effect of perindoprilat on expression of bradykinin B2 recep-
tor. Semiquantitative reverse transcription-polymerase chain reaction
(RT-PCR) was carried out on RNA from mesangial cells exposed to
MPCM ± perindoprilat for 18 hours. Southern blots were probed for
bradykinin B2 receptor. A representative blot from 10 experiments is
shown. Abbreviations are: MPCM, macrophage-conditioned medium;
Med, medium; ACE-I, angiotensin-converting enzyme inhibitor.
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Fig. 8. Effect of perindoprilat on the binding of H3-bradykinin to
MPCM-treated mesangial cells. Mesangial cells were treated with
MPCM ± perindoprilat for 18 hours. H3-bradykinin was added to the
mesangial cells to determine the level of surface bradykinin B2 re-
ceptor expression. Results are expressed as mean ± SEM (bradykinin
binding/lg cell protein). P = 0.002 vs. MPCM, N = 5. Abbreviations
are: MPCM, macrophage-conditioned medium; Med, medium; ACE-I,
angiotensin-converting enzyme inhibitor.
resulted in a reversal of the perindoprilat-mediated re-
duction in mesangial cell fibronectin levels (Fig. 9).
Effect of perindoprilat on the tissue plasminogen
activator system
The plasminogen activator system is also known to be
involved in extracellular matrix degradation. Bradykinin
has previously been shown to modulate levels of the fib-
rinolytic enzyme tPA [22], while ACE-I has been shown
to modulate levels of the tPA inhibitor PAI-1 [22]. Little
information is available in the literature about the ef-
fects of bradykinin or ACE-Is on urokinase plasminogen
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Fig. 9. Effect of bradykinin B2 receptor antagonist HOE 140 on the
antifibrotic effects of perindoprilat. Mesangial cells were treated with
MPCM + 40 lmol/L perindoprilat ± 1 lmol/L HOE 140 for 3 days.
Culture superntatants were assayed for fibronectin by enzyme-linked
immunosorbent assay (ELISA). Results are expressed as mean ± SEM
(fibronectin levels in treated cell supernatants are expressed as a fold-
increase over medium alone and corrected for cell protein). ∗P < 0.001
vs. MPCM, N = 6. Abbreviations are: MPCM, macrophage-conditioned
medium; Med, medium; ACE-I, angiotensin-converting enzyme
inhibitor.
activator (uPA) activity. In order to investigate a possible
link between the observed antifibrotic effects induced by
perindoprilat and the expression of these agents, mRNA
levels of tPA, uPA, and PAI-1 in MPCM-stimulated
mesangial cells in the presence or absence of perindo-
prilat were examined. Northern analysis revealed a 40 ±
8.0% (P = 0.006) increase in tPA mRNA levels following
ACE inhibitor treatment. uPA and PAI-1 mRNA levels
were not significantly affected (Fig. 10).
However, measuring total tPA protein levels by ELISA
demonstrated that tPA levels in the culture supernatants
of ACE-I treated cells were unexpectedly, significantly,
reduced by 14.0 ± 0.5% (P < 0.001) compared with non-
ACE-I–treated cells. uPA levels were not significantly
affected, while PAI-1 protein levels were reduced by
9.0 ± 0.25% (P < 0.001) (Fig. 11). Exogenous bradykinin
treatment of MPCM-stimulated mesangial cells followed
a similar pattern. Exogenous bradykinin reduced tPA lev-
els by 25.13 ± 2.37% (P < 0.001), had no significant ef-
fect on uPA levels, and reduced PAI-1 levels by 18.75 ±
1.38% (P = 0.02) compared with nonbradykinin-treated
cells (Fig. 12).
Effect of the bradykinin B2 receptor antagonist
HOE-140 on plasminogen activator system
In order to observe the effect of bradykinin B2 receptor
antagonism on components of the plasminogen activator
system, supernatants from MPCM-stimulated mesangial
cells treated with perinoprilat ± HOE 140 were analyzed
for tPA, uPA, and PAI-1 levels by ELISA. HOE 140 treat-
ment reversed the effects of perinoprilat on tPA and PAI-
MPCM MedMPCM
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ACE-I
Cyclophilin
PAI-1
tPA
uPA
Fig. 10. Effect of 40 lmol/L perindoprilat on plasminogen activator
system (mRNA levels). Northern analyses probing for tissue plas-
minogen activator (tPA), urokinase plasminogen activator (uPA), and
plasminogen activator inhibitor-1 (PAI-1) were carried out on RNA
extracted from mesangial cells treated with MPCM ± 40 lmol/L
perindoprilat for 18 hours. Representative blots from 3 experiments are
shown. Abbreviations are: MPCM, macrophage-conditioned medium;
Med, medium; ACE-I, angiotensin-converting enzyme inhibitor.
1 levels (Fig. 13), supporting the concept of a direct role
of the bradykinin B2 receptor in modulating the compo-
nents of the plasminogen activator system.
DISCUSSION
ACE-I are valuable therapeutic agents for the man-
agement of hypertension, and have specific benefits in
delaying the progression of chronic renal failure. While
the antihypertensive action of ACE-I may account for
their renoprotective effects, other mechanisms may also
be important. It is, therefore, of note that in studies in both
experimental animals and humans, other classes of anti-
hypertensive agents exhibited less renoprotection than
ACE-I, despite equivalent blood pressure control. Thus,
it would appear that the beneficial effects of ACE-I are
mediated by mechanisms in addition to, or independent
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Fig. 11. Effect of 40 lmol/L perindopri-
lat on tissue plasminogen activator (tPA)
system (protein levels). Supernatants from
mesangial cells treated ± ACE-I were an-
alyzed by enzyme-linked immunosorbent
assay (ELISA) for expression of total pro-
tein levels of tissue plasminogen activa-
tor (tPA), urokinase plasminogen activator
(uPA), and plasminogen activator inhibitor-
1 (PAI-1). Results are mean ± SEM.
tPA, uPA, PAI-1 levels in culture super-
natants are expressed as % of those in un-
treated MPCM-stimulated mesangial cells.
∗P < 0.001, N = 39, 18, 20, respectively.
Abbreviations are: MPCM, macrophage-
conditioned medium; Med, medium; ACE-I,
angiotensin-converting enzyme inhibitor.
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Fig. 12. Effect of exogenous bradykinin on
tissue plasminogen activator (tPA) system.
Supernatants from mesangial cells treated
with exogenous 0.1 lmol/L bradykinin were
analyzed by enzyme-linked immunosorbent
assay (ELISA) for the components of the
tissue plasminogen activator system (tPA),
urokinase plasminogen activator (uPA), and
plasminogen activator inhibitor-1 (PAI-1).
Results are mean ± SEM and expressed as
a % of those in untreated MPCM-stimulated
mesangial cells. ∗P = 0.007; ∗∗P = 0.02, N =
4. Abbreviations are: MPCM, macrophage-
conditioned medium; Med, medium; Bk,
bradykinin.
of, their systemic hemodynamic actions. These may
involve specific actions on intraglomerular hemodynam-
ics, but also include direct effects on the cellular produc-
tion of profibrotic cytokines and extracellular matrix. A
large body of evidence supports the hypothesis that the
effects of ACE inhibitors result from the inhibition of
Ang II formation. However, accumulating data also sug-
gest that some of their actions may be caused by reduced
bradykinin catabolism, with resultant accumulation of
endogenous bradykinin levels [23].
The current study has demonstrated that the antifi-
brotic effects of the ACE-I perindoprilat, in the con-
text of macrophage-induced mesangial cell injury, are
mediated, at least in part, by effects on the bradykinin
axis. RT-PCR demonstrated that mesangial cells have the
necessary biochemical machinery to generate endoge-
nous kinins. Moreover, we demonstrated that MPCM
treatment reduced basal mRNA levels of the bradykinin
precursor low kininogen, which were partially restored
following treatment with ACE-I. Addition of exogenous
bradykinin reduced MPCM-induced fibronectin levels in
mesangial cells, bradykinin B2 receptor mRNA levels
were up-regulated in the presence of perindoprilat, as
was binding of [H]3-bradykinin. Furthermore, inhibition
of B2 receptor activity with HOE 140 attenuated the
beneficial effects of perindoprilat treatment. Bradykinin
exerts most of its physiologic effects via the B2 recep-
tor, which is constitutively expressed in many cell types
[24]. There is increasing experimental evidence to sug-
gest that ACE-I may potentiate the effects of bradykinin
using mechanisms that are independent of their abil-
ity to inhibit ACE activity, per se [25–29]. For example,
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Fig. 13. Effect of bradykinin B2 receptor antagonist HOE 140 on tissue
plasminogen activator (tPA), urokinase plasminogen activator (uPA),
and plasminogen activator inhibitor-1 (PAI-1) levels in perindoprilat-
treated MPCM-stimulated mesangial cells. Supernatants from mesan-
gial cells treated ± ACE-I ± bradykinin B2 receptor antagonist HOE-
140 were analyzed by enzyme-linked immunosorbent assay (ELISA)
for the expression of total protein levels of tPA, uPA, and PAI-1. Re-
sults are mean ± SEM. tPA, uPA, and PAI-1 levels in culture super-
natants are expressed as a % of those in untreated MPCM-stimulated
mesangial cells. P < 0.001, N = 6 to 8). Abbreviations are: MPCM,
macrophage-conditioned medium; Med, medium; ACE-I, angiotensin-
converting enzyme inhibitor.
ACE inhibitors can potentiate bradykinin activity in the
presence of ACE-resistant bradykinin B2 receptor ag-
onists [26]. Furthermore, the bradykinin-potentiating ef-
fects of ACE-inhibitors are not mimicked by the synthetic
ACE substrate hippuryl-L-histidyl-L-leucine, which is as
equally effective at blocking bradykinin catabolism as
are ACE-I [26, 27]. Moreover, when B2 receptors are
desensitized and no longer responsive to extra agonist,
ACE inhibitors can reactivate B2 receptor-mediated sig-
naling [30]. Several possibilities may explain these phe-
nomena. There is evidence to suggest that ACE -I may
exert their effect directly on the bradykinin-B2 receptor
[26, 27], although ACE-I binding to receptor is yet to be
demonstrated [31]. It has also been suggested that bind-
ing of ACE-I to ACE results in a conformational change,
which is transduced directly to the B2 receptor in a sort
of ACE:B2 receptor “cross-talk” [30, 32]. It has been sug-
gested that the variability in ACE-I efficacy, as seen with
different molecules of the same class, may be dependent
on the ACE-I’s unique structural properties, which are
able to facilitate bradykinin B2 receptor signaling [25].
In the current study, bradykinin levels were signifi-
cantly reduced in day 3 culture supernatants of mesangial
cells treated with both MPCM and ACE-I compared with
MPCM alone, results which were contrary to what might
have been expected following inhibition of bradykinin
catabolism. However, these observations may be ex-
plained when increased ligation to an increased number
of receptors is taken into account.
The small increase in endogenous bradykinin lev-
els over control observed in response to MPCM alone
was probably insufficient to have a beneficial effect on
mesangial cells comparable to that of adding exogenous
bradykinin. Moreover, this slight increase is likely to be
under post-transcriptional control because mRNA levels
of the bradykinin precursor low kininogen in response to
MPCM were lower than basal mRNA levels.
Bradykinin has been shown to be a potent stimu-
lator of tPA in endothelial cells [33], perfused tissue
preparations [34], and in whole animals [35]. A study
by Brown et al [35] demonstrated that intravenous infu-
sion of bradykinin caused a significant increase in plasma
levels of tPA, which was further potentiated by treat-
ment with ACE-I. Bradykinin appeared to have no ef-
fect on PAI-1 levels [35]. Schanstra et al demonstrated
that transgenic rats overexpressing increased endoge-
nous bradykinin exhibited reduced interstitial fibrosis in
the unilateral ureteral obstruction model of renal injury.
Moreover, they demonstrated that genetic manipulation
or pharmacologic blockade of the bradykinin B2 receptor
increased interstitial fibrosis, and was accompanied by re-
duced activity of extracellular matrix degrading enzymes
[36].
In the present study, no measurable difference in the
expression of the matrix metalloproteinases 2, 3, or 9 fol-
lowing ACE-I treatment could be detected. However,
this was not the case for components of the plasmino-
gen activator system. Protein expression profiles of tPA
and PAI-1 were altered in response to ACE-I treatment.
The protein profiles differed from mRNA expression
levels, suggesting that the cells’ plasminogen activator
phenotype was modulated post-transcriptionally. This
pattern of plasminogen activator system expression fol-
lowing ACE treatment was echoed by addition of
exogenous bradykinin. Moreover, antagonism of the
bradykinin receptor resulted in a reversal of the effects
of perindoprilat on plasminogen activator components.
Together, these data lend support to the hypothesis that
ACE inhibition, with its resulting reduction in extracel-
lular matrix expression, involves bradykinin, its receptor,
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and the plasminogen activator system acting in a coordi-
nated manner.
The apparent paradoxic reduction in tPA protein lev-
els, though unexpected, may be explained by an increased
turnover of the protease via the ubiquitous low-density
lipoprotein receptor-related protein (LRP) [37]. LRP is
a multifunctional endocytic receptor implicated in the
modulation of a number of cellular processes, including
extracellular matrix accumulation and catabolism, and
the turnover of proteases, and protease/inhibitor com-
plexes. Noguchi et al have previously demonstrated that
in mouse hepatocytes interleukin-1b (IL-1b) was able
to up-regulate tPA mRNA levels while concomitantly
down-regulating tPA activity and protein levels by up-
regulating the expression of LRP [37]. A similar scenario
may account for our observations. However, investiga-
tions into this phenomenon are beyond the scope of the
current study.
CONCLUSION
This study provides further insight into the poten-
tial mechanisms underlying the unique renoprotective
actions of ACE-I. It demonstrates the importance of
bradykinin, its B2 receptor, and the plasminogen acti-
vator system in modulating the renoprotective effects of
ACE-I.
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